ABBV phase-3 trials in presbyopia hit primary endpoint Interesting, might be why EYEN is pushing harder on the Myopia trial and partnering with Bausch and Lomb for this application. "Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12" https://www.prnewswire.com/news-releases/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12-301149863.html